Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders Francisco Navarrete, María Salud García-Gutiérrez, Ani Gasparyan, Amaya Austrich-Olivares and Jorge Manzanares Frontiers in Pharmacology, 2021, 12, Article 696010, 1-24. Doi : 10.3389/fphar.2021.626010 Drug treatments available for the management of substance use disorders (SUD) present multiple limitations in efficacy, lack of approved treatments or alarming relapse rates. These facts hamper the clinical outcome and the quality of life of the patients supporting the importance to develop new pharmacological agents. Lately, several reports suggest that cannabidiol (CBD) presents beneficial effects relevant for the management of neurological disorders such as epilepsy, multiple sclerosis, Parkinson’s, or [...]
Lire la suiteCB2 Receptor Involvement in the Treatment of Substance Use Disorders Francisco Navarrete, María S. García-Gutiérrez, Ani Gasparyan, Daniela Navarro and Jorge Manzanares Biomolecules, 2021, 11, 1556, 1-18. Doi : 10.3390/biom11111556 Abstract The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level by assessing evidence from preclinical and clinical studies. In rodents, several reports suggest the functional involvement of CB2r in the effects produced by drugs of abuse such [...]
Lire la suiteLearning to Let Go : A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance Max Wolff, Ricarda Evens, Lea J. Mertens, Michael Koslowski, Felix Betzler, Gerhard Gründer and Henrik Jungaberle Frontiers in Psychiatry, February 2020 | Volume 11 | Article 5, 1-13. doi : 10.3389/fpsyt.2020.00005 The efficacy of psychedelic-assisted therapies for mental disorders has been attributed to the lasting change from experiential avoidance to acceptance that these treatments appear to facilitate. This article presents a conceptual model that specifies potential psychological mechanisms underlying such change, and that shows substantial parallels between psychedelic therapy and cognitive behavioral therapy: We propose that in the carefully controlled [...]
Lire la suitePsychedelic Medicines for Mood Disorders Current Evidence and Clinical Considerations Jerome Sarris; Diego Pinzon Rubiano; Kimberley Day; Nicole L. Galvão-Coelho; Daniel Perkins Current Opinion in Psychiatry, 2022, 35, (1), 22-29. doi : 10.1097/YCO.0000000000000759 https://www.medscape.com/viewarticle/964245 Abstract and Introduction Abstract Purpose of Review: Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions. Recent Findings: Serotonergic psychedelics have been found to modulate brain networks underlying various psychiatric disorders, as well promoting neurogenesis and neuroplasticity. Randomized placebo-controlled trials have found psilocybin with psychological support effective at [...]
Lire la suiteNovel Treatment Approaches for Substance Use Disorders : Therapeutic Use of Psychedelics and the Role of Psychotherapy Michael Koslowski, Matthew W. Johnson, Gerhard Gründer, Felix Betzler Current Addiction Reports, 2021, 1-11. doi : 10.1007/s40429-021-00401-8 Abstract Purpose of Review : The use of psychedelics in a therapeutical setting has been reported for the treatment of various diagnoses in recent years. However, as psychedelic substances are still commonly known for their (illicit) recreational use, it may seem counterintuitive to use psychedelic therapy to treat substance use disorders. This review aims to discuss how psychedelics can promote and intensify psychotherapeutic key processes, in different approaches like psychodynamic and [...]
Lire la suitePharmacologie du Cannabidiol : Points de vigilance, conséquences et risques chez l’homme Note rédigée par l’Association Française des centres d’Addictovigilance : Pr Joëlle MICALLEF, Dr Anne BATISSE, Dr Bruno REVOL, décembre 2021 Contexte Le Cannabidiol (CBD) est l’un des principaux phytocannabinoïdes présent dans Cannabis sativa, avec le THC. A ce jour, un seul produit contenant uniquement du CBD (nom de ce médicament Epidyolex®) est disponible sur le marché français, son Autorisation de Mise sur le Marché (AMM) lui conférant une indication médicale en association au clobazam dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut ou au syndrome de Dravet, chez les [...]
Lire la suiteL’INDISPENSABLE SUR... LE CANNABIDIOL (CBD) MILDECA Mission interministérielle de lutte contre les drogues et les conduites addictives 2021 Qu’est-ce que le cannabidiol ? C’est : une des principales substances actives de type cannabinoïde de la plante de chanvre, au même titre que le THC (delta-9-tétrahydrocannabinol). On la trouve principalement au niveau de la fleur et des feuilles adjacentes. un composant, sous forme d’extrait, de médicaments ou de produits de consommation courante, dont seuls certains sont autorisés en France. Ce n’est pas : un stupéfiant. Le CBD reste tout de même une substance à effet psychoactif, qui peut avoir des interactions avec d'autres molécules, notamment des médicaments. une [...]
Lire la suiteMedical cannabis authorization and the risk of cardiovascular events : a longitudinal cohort study Arsene Zongo, Cerina Lee, Jason R. B. Dyck, Jihane El‑Mourad, Elaine Hyshka, John G. Hanlon and Dean T. Eurich BMC Cardiovascular Disorders, 2021, 21, 426 doi : 10.1186/s12872-021-02229-6 Abstract Background : Cannabis is increasingly used for therapeutic purpose. However, its safety profile is not well known. This study assessed the risk of cardiovascular-related emergency department (ED) visit and hospitalization in adult patients authorized to use medical cannabis in Ontario, Canada from 2014 to 2017. Methods : This is a longitudinal cohort study of patients who received medical cannabis authorization and followedup in [...]
Lire la suiteScoping Review and Meta-Analysis Suggests that Cannabis Use May Reduce Cancer Risk in the United States Thomas M. Clark Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 413-434. Doi : 10.1089/can.2019.0095 Abstract Introduction:Cannabis smoke contains carcinogens similar to tobacco, in addition to compounds with antitumor activity. Cannabis use reduces the risk of obesity and cannabinoids inhibit chronic inflammation, known causes of cancer. The net effect of Cannabis use on cancer risk is not known. Objective: To examine the association between Cannabis use and cancer risk in the United States. Methods: Identify and analyze published data on cancer risk in Cannabis users. Results: A total of 55 data [...]
Lire la suiteCannabinoid CB2 Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression Carmen A. Zavala, Ana C. Thomaz, Vishakh Iyer, Ken Mackie, and Andrea G. Hohmann Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 389-400. DOI: 10.1089/can.2020.0059 Abstract Introduction : Overdose fatalities associated with the opioid epidemic are predictably attributable to druginduced respiratory depression. In terms of illicit opioid abuse, fentanyl is the synthetic opioid responsible for the largest number of overdose deaths. There is, therefore, an urgent need to identify safe and effective therapeutics that can attenuate fentanyl-induced respiratory depression. Identification of effective alternate analgesic strategies that lessen the respiratory depression associated with narcotics would also help [...]
Lire la suite